 |
JOHANNESBURG, 10 May 2012 (PLUSNEWS) – The Global Fund to fight AIDS, Tuberculosis and Malaria has announced that it will have US$1.6 billion more to invest in life-saving programmes between 2012 and 2014. |
HIV/AIDS: Global Fund will have US$1.6 billion more
Biosensor illuminates compounds to aid fight against TB
Gates Foundation funds project to find new treatments
EAST LANSING, Mich. — For his work on developing new treatments for tuberculosis, a Michigan State University researcher has been named a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.
Robert Abramovitch of MSU’s Department of Microbiology and Molecular Genetics is using a synthetic biosensor that glows green in response to conditions that mimic human tuberculosis infection. He will screen for compounds that target chronic TB infection and may help shorten therapy or treat multidrug-resistant TB, which does not respond well to existing antibiotics. Read More
Evaluation of the clinical value of ELISA based onMPT64 antibody aptamer for serological diagnosisof pulmonary tuberculosis
Background:
Presently, tuberculosis (TB) poses a global threat to human health. The development ofreliable laboratory tools is vital to the diagnosis and treatment of TB. MPT64, a proteinsecreted by Mycobacterium tuberculosis complex, is highly specific for TB, making antibodyto MPT64 a reagent specific for the diagnosis of TB Read More
Point-of-care detection of lipoarabinomannan (LAM) inurine for diagnosis of HIV-associated tuberculosis: a stateof the art review
Detection of Mycobacterium tuberculosis antigens in urine is attractive as a potential meansof diagnosing tuberculosis (TB) regardless of the anatomical site of disease. The mostpromising candidate antigen is the cell wall lipopolysaccharide antigen lipoarabinomannan(LAM), which has been used to develop commercially available enzyme-linkedimmunosorbent assays Read More
Similar Products: Powered by 
 |
The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop :: Amazon An estimated 2 billion people, one third of the global population, are infected with Mycobacterium tuberculosis, the bacterium that causes t |
 |
Antituberculosis Chemotherapy (Progress in Respiratory Research) :: Amazon Tuberculosis (TB) remains one of the major infectious diseases of mankind although drugs for its treatment have been available for nearly 60 |
Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study
Background:
HIV and tuberculosis (TB) are commonly associated. Identifying latent and asymptomatic tuberculosis infection in HIV-positive patients is important in preventing death and morbidity associated with active TB. Read More
SWAZILAND: Nurses demand protection from TB infection
 |
MBABANE, 26 April 2012 (PLUSNEWS) – Hospitals are not protecting their workers from tuberculosis (TB) infection, say nurses in Swaziland, who recently staged a rare public demonstration to draw attention to how vulnerable they are to this highly infectious disease. |
Vaccine for Neglected Disease Ready for Testing
LISBON – During a meeting in Lisbon, the partners of the BuruliVac research consortium found the project to be running smoothly, and getting closer to a vaccine against Buruli ulcer, a disfiguring and mutilating disease that causes a lot of suffering and now is difficult to treat. Several vaccine candidates work well in mice and are ready for further testing on blood of patients; one is ready for testing in mice. Scientists of the Antwerp Institute of Tropical Medicine play an important role in this endeavour. Read More
[Comment] New studies of BCG: implications for tuberculosis vaccines
BCG has been given to over 3 billion people since the early part of the 20th century. Although the vaccine is effective, its use was implemented before clinical-trial design had reached its current sophistication, and before sensitive in-vitro techniques of assessing cellular immune responses were available. Recent studies and reinterpretation of previous trials have helped to clarify the true efficacy of BCG against both infection with and disease caused by Mycobacterium tuberculosis, while large cohort studies have provided an accurate side-effect profile in recipients with HIV infection.
Go to Source
[Comment] Operational research and MDG tuberculosis control targets
Tuberculosis continues to be a global emergency. In 2010, there were 8·8 million incident cases and 1·45 million deaths from tuberculosis, of which 0·35 million deaths were due to HIV-associated tuberculosis. The Millennium Development Goal (MDG) target to stop the spread of tuberculosis and reduce mortality by 50% by 2015 seems to be on track for all global regions, but is remote for sub-Saharan Africa. While new drugs and vaccines are in development, the answer to achieving the MDG aim universally, and particularly in sub-Saharan Africa, rests on programmatic and operational issues.
Go to Source
CD4 lymphocyte dynamics in Tanzanian pulmonary tuberculosis patients with and without HIV co-infection
Background:
The interaction of HIV and tuberculosis (TB) on CD4 levels over time has previously been divergently reported and only in small study populations with short or no follow-up. Read More
TB Alliance launches combination drug trial, establishes new pathway to TB and MDR-TB treatment
Goal is to find new treatment that takes months, not years, and cures multiple forms of tuberculosis; announcement made at World TB Day briefing featuring senior US government officials
WASHINGTON, D.C. (19 March 2012) – In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical trial to test a novel drug combination – in both patients who have TB, and those who have multidrug-resistant TB (MDR-TB). Read More
Award to Aeras boosts historic hunt for new TB vaccines, as drug resistance proliferates
Grant represents vital step in meeting urgent global need to fund worldwide scientific efforts to eliminate airborne threat
Rockville, MD, USA | Cape Town, South Africa (March 15, 2012) – Aeras announces today the receipt of a grant by the Bill & Melinda Gates Foundation of up to US $220 million over five years, placing it at the forefront of a global scientific initiative aimed at developing safe, effective vaccines against tuberculosis, a disease that infects two billion people worldwide. Read More
Disease Outbreaks- Avian influenza – situation in Indonesia – updateThe Indonesian IHR National Focal Point of the Ministry of Health has notified WHO of a new case of human infection with avian influenza A(H5N1) virus. […]
- Avian influenza – situation in Egypt – updateThe Ministry of Health and Population of Egypt has notified WHO of a new case of human infection with avian influenza A (H5N1) virus. […]
- Avian influenza – situation in Cambodia – updateThe Ministry of Health (MoH) of the Kingdom of Cambodia has announced a confirmed case of human infection with avian influenza A (H5N1) virus. […]
- Lassa fever in NigeriaAt the beginning of 2012, WHO was notified by the Federal Ministry of Health in Nigeria of an outbreak of Lassa fever. As of March 22, 2012, 623 suspected cases, including 70 deaths have been recorded from 19 of the 36 States since the beginning of the year. Laboratory analysis undertaken at the Irrua Specialist Teaching Hospital, Irrua Edo State has confirm […]
- Avian influenza – situation in Egypt – updateThe Ministry of Health and Population of Egypt has notified WHO of two new cases of human infection with avian influenza A (H5N1) virus. […]
- Avian influenza – situation in Indonesia – update
Cheap Calls to Kenya
-
Mendeley Related Research
0
Readers1
Readers4
ReadersVaccine approaches to prevent tuberculosis.Array (2006)7
Readers5
ReadersRecent progress in mycobacteriologyArray (2007)